Author:
Nangola Sawitree,Urvoas Agathe,Valerio-Lepiniec Marie,Khamaikawin Wannisa,Sakkhachornphop Supachai,Hong Saw-See,Boulanger Pierre,Minard Philippe,Tayapiwatana Chatchai
Abstract
Abstract
Background
Ankyrins are cellular mediators of a number of essential protein-protein interactions. Unlike intrabodies, ankyrins are composed of highly structured repeat modules characterized by disulfide bridge-independent folding. Artificial ankyrin molecules, designed to target viral components, might act as intracellular antiviral agents and contribute to the cellular immunity against viral pathogens such as HIV-1.
Results
A phage-displayed library of artificial ankyrins was constructed, and screened on a polyprotein made of the fused matrix and capsid domains (MA-CA) of the HIV-1 Gag precursor. An ankyrin with three modules named AnkGAG1D4 (16.5 kDa) was isolated. AnkGAG1D4 and MA-CA formed a protein complex with a stoichiometry of 1:1 and a dissociation constant of K
d ~ 1 μM, and the AnkGAG1D4 binding site was mapped to the N-terminal domain of the CA, within residues 1-110. HIV-1 production in SupT1 cells stably expressing AnkGAG1D4 in both N-myristoylated and non-N-myristoylated versions was significantly reduced compared to control cells. AnkGAG1D4 expression also reduced the production of MLV, a phylogenetically distant retrovirus. The AnkGAG1D4-mediated antiviral effect on HIV-1 was found to occur at post-integration steps, but did not involve the Gag precursor processing or cellular trafficking. Our data suggested that the lower HIV-1 progeny yields resulted from the negative interference of AnkGAG1D4-CA with the Gag assembly and budding pathway.
Conclusions
The resistance of AnkGAG1D4-expressing cells to HIV-1 suggested that the CA-targeted ankyrin AnkGAG1D4 could serve as a protein platform for the design of a novel class of intracellular inhibitors of HIV-1 assembly based on ankyrin-repeat modules.
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Virology
Reference85 articles.
1. Arora DR, Gautam V, Gill PS, Mishra N: Recent advances in antiretroviral therapy in HIV infection. J Indian Med Assoc. 2010, 108: 29-34.
2. Check E: Pioneering HIV treatment would use interference and gene therapy. Nature. 2005, 437: 601-
3. Luque F, Oya R, Macias D, Saniger L: Gene therapy for HIV-1 infection: are lethal genes a valuable tool?. Cell Mol Biol. 2005, 51: 93-101.
4. Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, Manrique A, Huber M, Rehr M, Oxenius A, Weber R, Stiegler G, Vcelar B, Katinger H, Aceto L, Günthard HF: Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med. 2005, 11: 615-622. 10.1038/nm1244.
5. von Laer D, Hasselmann S, Hasselmann K: Gene therapy for HIV infection: what does it need to make it work?. J Gene Med. 2006, 8: 658-667.
Cited by
33 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献